Hong Kong stock focus: BYD's sales of new energy vehicles increased by 218% in 2021; Xiaomi repurchased 1.57 million shares

【Today's Focus】

BYD sold more than 740,000 units in 2021, and sales of new energy vehicles increased by 218.3% year-on-year

BYD (01211.HK) disclosed that in December 2021, production was 97,274 units, an increase of 71.97% year-on-year, and sales were 99,112 units, an increase of 75.97% year-on-year. Among them, the sales volume of new energy vehicles was 93,945 units, an increase of 225.73% year-on-year. From January to December 2021, cumulative production was 747,540 units, up 74.79% year-on-year, and cumulative sales were 740,131 units, up 73.34% year-on-year. Among them, the cumulative sales of new energy vehicles were 603,783 units, an increase of 218.30% year-on-year. In addition, the company's total installed capacity of new energy vehicle power batteries and energy storage batteries in December 2021 was about 5.049GWh, and the cumulative installed capacity in 2021 was about 37.921GWh. In December 2021, the company's new energy vehicle order demand continued to be strong and maintained a sustained growth momentum; affected by the epidemic in Xi'an in the second half of the year, the output of the company's Xi'an automobile production base was affected to a certain extent, and the production of the Xi'an base has basically returned to normal as of now.

Hengteng Network signed a cooperation agreement with Tencent Computer

Hengteng Network (00136.HK) announced that Shenzhen Jingxiu, a subsidiary of the Company, and Tencent Computer, a subsidiary of Tencent Holdings (00700.HK), signed a cooperation agreement on January 3, 2022, in which the two parties agreed that Tencent Computer (and/or its subsidiaries) would provide, among other things, technical services and channel promotion services to the Group's game products on the Chinese mainland. In view of Tencent Group's extensive experience in game product development and operation and is one of the integrated Internet service providers in China, the Group plans to cooperate with Tencent Holdings in the game business. The directors believe that the cooperation with Tencent Holdings' game business can broaden the company's entertainment business scope, and at the same time enhance the company's film and television intellectual property realization ability through film-game linkage, and in the long run, it will help the group enrich its talent reserves, enhance its scientific and technological strength, and help the company's development enter a new stage.

Youzan's store SaaS business commodity trading volume increased by more than 100% in 2021

China Youzan (08083.HK) announced that for the year ended 31 December 2021, the total amount of commodity transactions generated by Group merchants through Youzan's solutions reached approximately RMB98.3 billion, of which the total amount of commodity transactions from non-Kuaishou channels increased by more than 30% year-on-year compared with 2020. The store SaaS business has achieved rapid development in 2021, the number of new store SaaS merchants has increased significantly, and the total proportion of commodity transactions in the store SaaS business has increased significantly to 28%, an increase of more than 100% year-on-year.

Federal Pharmaceuticals (03933. HK) intends to further repurchase up to AN ADDITIONAL HK$50 million in shares

Federal Pharmaceuticals (03933.HK) has issued an announcement regarding the purchase of up to HK$50 million under a general mandate. The Board intends to exercise its powers under the repurchase authorization to spend up to AN ADDITIONAL HK$50 million to further repurchase shares in the open market at an appropriate time. The Company will subsequently cancel the repurchased shares. The proposed share repurchase will be paid in internal cash. The Board firmly believes that the Company currently has a sound financial position and believes that the proposed share repurchase is in the overall interest of the Company and its shareholders. It is recommended that share repurchases and subsequent cancellations of repurchased shares increase the value of shares and improve shareholder returns.

and Platinum Pharma-B (02142): Two HBM4003 Phase I trials completed the first dose to the first patient

HeboMed-B (02142.HK) announced that in the HBM4003 Clinical Phase I trial, the company completed two first doses of drug administration to the first patient for the treatment of advanced hepatocellular carcinoma and other solid tumors, as well as for the treatment of advanced neuroendocrine tumors and other solid tumors. HBM4003 is the next generation of anti-CTLA-4 fully human heavy chain antibody (HCAb) developed by the company. The objective of this clinical study was to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and preliminary efficacy of the combination of HBM4003 and torrepalizumab (PD-1 antibody) in patients with Hepatocellular carcinoma, neuroendocrine tumors and other solid tumors in China.

【Operating Data】

Lico Group's contracted sales in 2021 reached 47.011 billion yuan

【M&A sale】

Wind Clean Energy (01165.HK) plans to sell solar power generation assets for 890 million yuan and resume trading tomorrow

【Investment and Operation】

Zero2IPO Venture (01945.HK): Obtained Type 4 and Type 9 licenses from the Securities and Futures Commission of Hong Kong

Beikong Urban Resources (03718.HK) won the bid for 152 million yuan for the urban and rural sanitation integration service procurement project

Baguio Green Group (01397.HK) wins the bid for an EPD contract to bio-convert chicken manure into animal feed and fertilizer

Rongchang Bio claimed that the allegations made in the report were unfounded and contained a number of misrepresentations

Building Blocks Group (08187.HK) terminates the share subscription agreement and resumes trading tomorrow

Guancheng Watch & Jewelry (00256.HK) terminated the sale of its watch and clock timing products company

【Repurchase Cancellation】

Xiaomi spent HK$29.28 million to buy back 1.575 million shares on January 3

Shuncheng (00531.HK) intends to repurchase shares

CSPC Pharmaceutical Group spent HK$17.4087 million to repurchase a total of 2.054 million shares on January 3

Ping An Good Doctor spent HK$13,097,800 to buy back 480,000 shares on January 3

HSBC Holdings spent £6.3775 million to repurchase 1.4249 million shares on December 31

Tianlun Gas (01600.HK) spent HK$6.6351 million to repurchase 800,000 shares on January 3

Liwen Paper (02314) spent HK$4.121 million to repurchase 764,000 shares on January 3

Federal Pharmaceutical (03933.HK) spent HK$2.575 million to repurchase 584,000 shares on January 3

NetDragon (00777.HK) spent HK$3.6331 million to buy back 200,000 shares on January 3

Huiliang Technology (01860.HK) spent HK$1.3324 million to repurchase 193,000 shares on January 3

【Equity Incentive】

China Agricultural Products Exchange (00149.HK) granted a total of 226 million stock options

Jiuxing Holdings (1836. HK) granted a total of 19.74 million share options

Syndec Medical adopts the Share Award Scheme

Midland Industrial & Commercial Shop (00459.HK) granted 54 million stock options

Shenyou Holdings (08377.HK) granted 4.0914 million share options